Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824975 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by GI Innovation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 358
- Enrollment target
- 11
- Study locations
NCT05824975 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is actively recruiting participants, run by GI Innovation. The registered enrollment target is 358 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (87% higher). The trial reports 11 study locations across 8 states.
The verdict
NCT05824975, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is actively recruiting participants, sponsored by GI Innovation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 358 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG bevacizumab
- DRUG GI-102 subcutaneous (SC)
- DRUG GI-102
- DRUG doxorubicin
- DRUG paclitaxel
Study Locations (11)
Other
- Yonsei University Health System, Severance Hospital - Seoul
- Yonsei University Health System, Severance Hospital - Seoul
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
Arizona
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Minnesota - Rochester
New York
- Memorial Sloan-Kettering Cancer Center - New York
Ohio
- Cleveland Clinic - Cleveland
Seoul
- Seoul National University Hospital - Seoul
suwon
- St. Vincent's Hospital - Suwon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2023-05-30 |
| Est. Completion | 2027-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05824975
The ClinicalTrials.gov registry entry for NCT05824975 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (87% higher). The listed sponsor is GI Innovation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which bevacizumab is the first listed.
NCT05824975 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT05824975 about?
NCT05824975 is a clinical study titled "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
What is the current status of trial NCT05824975?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 358 participants. The study started on 2023-05-30. Estimated completion is 2027-04-24.
What conditions does trial NCT05824975 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor, HER2-Negative Breast Cancer, Cutaneous Melanoma, Colorectal Cancer (CRC).
What interventions are being tested in trial NCT05824975?
The interventions under investigation include: bevacizumab (DRUG), GI-102 subcutaneous (SC) (DRUG), GI-102 (DRUG), doxorubicin (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT05824975?
This trial is sponsored by GI Innovation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05824975 being conducted?
This trial has 11 study locations across Arizona, Florida, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.